Personalized Gastric Cancer Treatment: Recent Progress and Future Perspectives
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Precision Oncology".
Deadline for manuscript submissions: 10 August 2026 | Viewed by 26
Special Issue Editor
Special Issue Information
Dear Colleagues,
The treatment paradigm in patients with gastric cancer has changed drastically in recent years. In the metastatic setting, based on biomarker testing, we have many approved combination regimens in the first-line setting, including agents targeting HER2 (e.g., trastuzumab), CLDN18.2 (e.g., zolbetuximab), PD-L1 CPS (e.g., pembrolizumab, nivolumab, and tislelizumab), and MSI-H (e.g., pembrolizumab, nivolumab/ipilimumab, and dostarlimab). In the perioperative setting, we are seeing positive results with moving agents to earlier stages, as shown in the recently reported MATTERHORN study where durvalumab was combined with systemic chemotherapy. Despite our success, there remains an unmet need to improve outcomes for patients, as our current treatments risk high recurrence rates, toxicity, and persistently low survival outcomes. Therefore, this Special Issue aims to collate high-quality studies, including original research and reviews, exploring the association of biomarkers with gastric cancer outcomes.
Dr. Gagandeep Brar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gastric cancer
- biomarkers
- targeted therapy
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
